VKTX
Viking Therapeutics, Inc.
Next earnings Jul 21, 2026 (after close) · consensus $-1.24 EPS
Last earnings -3.3% on 2026-04-29
$38.04
▲ +2.84%$38.04▲ +53.02%
over 1Y
L $23.09EODHDH $42.09
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.8%
1W+17.5%
1M+20.2%
3M+17.0%
YTD+7.4%
1Y+53.0%
Hold
Conviction
Horizon
Long (>12mo)
Street · 26 analysts
Buy
Phase 3 obesity story with cash to fund it, but $0 revenue and a $279M cash burn make this a binary VANQUISH bet, not an investment.
Revenue $0.00 · FY2025
Viking is a pure clinical-stage biotech whose entire equity value hinges on VK2735, a dual GLP-1/GIP agonist for obesity. The Phase 2 VENTURE data the 10-K cites — up to 14.7% weight loss from baseline and 13.1% placebo-adjusted at 13 weeks — is genuinely competitive with the incumbent injectables, and the August 2025 oral VENTURE-Oral trial hit primary and secondary endpoints with a clean tolerability profile. With VANQUISH-1 enrollment completed in November 2025 and Phase 3 oral dosing slated for Q3 2026, the catalyst calendar is real and near-term, which explains why the stock is up 8.8% today.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$55.7M | -$70.4M | -$101M | -$151M | -$393M |
| Net income | -$55.0M | -$68.9M | -$85.9M | -$110M | -$360M |
| Diluted EPS | -$0.71 | -$0.90 | -$0.91 | -$1.01 | -$3.19 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$4.23B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-8.2%
FCF yield—
Quality & risk
ROIC (est.)-48.6%
Free cash flow—
Total debt—
Net cash$166M
Altman Z-Score32.00 safe
Piotroski F-Score1/7
Capital returns
Buyback yield0.2%
Dividend yield (est.)—
Shareholder yield0.2%
Shares Δ YoY+2.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has been improving.
- 8-K Shareholder vote2026-05-26
Annual meeting vote results disclosed; routine governance with no operational change.
- 10-Q Quarterly report2026-04-30
Q1'26 10-Q: pre-revenue, deepening loss; pipeline progresses toward oral Phase 3 in Q3'26.
- 8-K Earnings results2026-04-29
Q1'26 earnings: no revenue, R&D burn accelerates funding two Phase 3 VANQUISH studies.
- DEF 14A Proxy statement2026-04-01
2026 proxy: routine director/auditor votes and exec comp; no material business change.
- 8-K Earnings results2026-02-11
FY25 10-K: VANQUISH-1 enrollment done, oral Phase 2 positive; $166M cash, losses widening.
- 10-K Annual report2026-02-11
FY25 10-K: VANQUISH-1 enrollment done, oral Phase 2 positive; $166M cash, losses widening.
- 10-Q Quarterly report2025-10-23
Q3'25 10-Q filed alongside Phase 3 ramp; rising opex against zero revenue base.
- 8-K Earnings results2025-10-22
Q3'25 update post Phase 3 launch; widening loss reflects VANQUISH-1/2 enrollment costs.
- 8-K Reg FD disclosure2025-08-19
Reg FD: positive Phase 2 VENTURE-Oral topline — oral VK2735 hit weight-loss endpoints.
Recent filings
all on EDGAR ↗4Period ending 2026-06-012026-06-03open ↗3Period ending 2026-06-012026-06-03open ↗8-KPeriod ending 2026-05-192026-05-26open ↗SCHEDULE 13GFiling2026-04-30open ↗10-QPeriod ending 2026-03-312026-04-30open ↗8-KPeriod ending 2026-04-292026-04-29open ↗ARSPeriod ending 2025-12-312026-04-01open ↗DEFA14AFiling2026-04-01open ↗DEF 14APeriod ending 2026-05-192026-04-01open ↗SCHEDULE 13G/AFiling2026-03-27open ↗4Period ending 2026-03-102026-03-10open ↗10-KPeriod ending 2025-12-312026-02-11open ↗
Frequently asked
- Is Viking Therapeutics, Inc. (VKTX) a buy?
- VKTX currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Phase 3 obesity story with cash to fund it, but $0 revenue and a $279M cash burn make this a binary VANQUISH bet, not an investment.
- What is Viking Therapeutics, Inc.'s quality score?
- VKTX scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001607678, latest 10-Q filed 2026-04-30) · EODHD · analysis by claude-code · as of 6/25/2026, 12:55:51 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.